Showing 1521-1530 of 1692 results for "".
- Individuals With Poorly Controlled Type 1 Diabetes May Have More Risk of Dementiahttps://practicalneurology.com/news/individuals-with-poorly-controlled-type-1-diabetes-may-have-more-risk-of-dementia/2469604/According to research published in Neurology, individuals with type 1 diabetes who have been to the hospital at some point for hypo- or hyperglycemia may be at 6 times more risk for developing dementia years later. The study found individuals with type 1 diabetes who visited the hospital
- Opioid Use for Migraine Treatment Remains High, Especially in Emergency Departmenthttps://practicalneurology.com/news/opioid-use-for-migraine-treatment-remains-high-especially-when-treatment-occurs-in-the-emergency-department/2468955/A retrospective analysis of electronic health records from 2010 through 2016 evaluated 14,494 emergency department visits for migraine. In 23%, opioids were given within 12 hours of presentation. When opioids were given, they were the first therapy given more than half the time (58%). Likelihood
- New FDA-Cleared Software Update Enhances MRI Analysis for ARIA Detectionhttps://practicalneurology.com/news/new-fda-cleared-software-update-enhances-mri-analysis-for-aria-detection/2470568/NeuroQuant v5.0 (Cortechs.ai, San Diego, CA), the latest update to NeuroQuant (Cortechs.ai, San Diego, CA) neuroimaging analysis software, has received Food and Drug Administration (FDA) 510(k) clearance. The update enables the identification and evaluation of focal brain lesions in MRI images, w
- Advances in Preventive Treatment of Migraine Continuehttps://practicalneurology.com/news/advances-in-preventive-treatment-of-migraine-continue/2469756/At the Scottsdale Headache Symposium, the latest pharmacologic treatments for prevention of episodic migraine were reviewed. The focus remained on pharmacologic therapies that inhibit or block the effects of calcitonin gene-related peptide (CGRP) and its receptor—the first preventive treatm
- Update on Migraine Incidence and Risk for Progression from Episodic to Chronic Migrainehttps://practicalneurology.com/news/update-on-migraine-incidence-of-migraine-and-risk-for-progression-from-episodic-to-chronic-migraine/2469439/At the Virtual Scottsdale Headache Symposium 2020, Richard Lipton, MD presented the latest data from epidemiology studies of migraine. Dr. Lipton noted that epidemiologic studies not only provide a conceptual model of the disease and approaches for better understanding but also help to assess and
- Imaavy Outperforms Other FcRn Blockers in Sustained gMG Symptom Controlhttps://practicalneurology.com/news/imaavy-outperforms-other-fcrn-blockers-in-sustained-gmg-symptom-control/2475453/Results of an indirect treatment comparison (ITC) demonstrated that Imaavy (nipocalimab-aahu; Johnson & Johnson, New Brunswick, NJ) treatment was associated with consistent and sustained improvement in generalized myasthenia gravis (gMG) symptoms in individuals aged ≥12 years with anti-acetyl
- New Study Uncovers Novel Link Between Football Players, CTE, and Health Problemshttps://practicalneurology.com/news/new-study-uncovers-novel-link-between-football-players-cte-and-health-problems/2470605/Study results published in JAMA Neurology showed that approximately one-third of living former professional American-style football (ASF) players believe they have chronic traumatic encephalopathy (CTE), and this perception is associated with a higher prevalence of suicidality
- FDA Grants Clearance to OneRF Trigeminal Nerve Ablation System for Facial Painhttps://practicalneurology.com/news/fda-grants-clearance-to-onerf-trigeminal-nerve-ablation-system-for-facial-pain/2483016/The Food and Drug Administration (FDA) has granted 510(k) clearance to the OneRF Trigeminal Nerve Ablation System (NeuroOne Medical Technologies Corporation [NeuroOne], Eden Prairie, MN), authorizing its use for the treatment of pain or for lesioning nerve tissue during neurosurgical procedures t
- FDA Greenlights Phase 2a Trial of Intranasal Foralumab in Multiple System Atrophyhttps://practicalneurology.com/news/fda-greenlights-phase-2a-trial-of-intranasal-foralumab-in-multiple-system-atrophy/2476103/The Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application, permitting the evaluation of treatment with intranasal foralumab (Tiziana Life Sciences, New York, NY) for people with multiple system atrophy (MSA) in a phase 2a clinical trial (NCT06868628). MSA i
- Seizure Freedom During Pregnancy Strongly Predicts Postpartum Seizure Controlhttps://practicalneurology.com/news/seizure-freedom-during-pregnancy-strongly-predicts-postpartum-seizure-control/2474277/For people with epilepsy of childbearing potential (PWECP) seizure freedom during pregnancy was shown to be a strong predictor of seizure freedom in the postpartum period. This finding from an analysis of results of the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONE